(0.28%) 5 145.75 points
(0.15%) 38 500 points
(0.44%) 17 925 points
(-0.72%) $83.25
(1.56%) $1.953
(-0.12%) $2 344.50
(0.04%) $27.55
(2.75%) $947.50
(-0.07%) $0.934
(-0.14%) $11.01
(-0.28%) $0.798
(1.85%) $93.57
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 17.61%
@ $3.65
发出时间: 15 Feb 2024 @ 02:53
回报率: 27.67%
上一信号: Feb 14 - 00:05
上一信号:
回报率: -1.62 %
Live Chart Being Loaded With Signals
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform...
Stats | |
---|---|
今日成交量 | 407 036 |
平均成交量 | 896 177 |
市值 | 569.84M |
EPS | $0 ( 2024-03-06 ) |
下一个收益日期 | ( $-0.180 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -8.63 |
ATR14 | $0.00600 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Moran Kyle | Sell | 15 630 | Ordinary Shares |
2024-02-05 | Francis Chris | Buy | 286 400 | Share Option (right to buy) |
2024-02-05 | Bolno Paul | Buy | 1 008 600 | Share Option (right to buy) |
2024-02-05 | Moran Kyle | Buy | 371 500 | Share Option (right to buy) |
2024-02-05 | Vargeese Chandra | Buy | 361 700 | Share Option (right to buy) |
INSIDER POWER |
---|
98.57 |
Last 99 transactions |
Buy: 37 730 786 | Sell: 301 457 |
音量 相关性
WAVE Life Sciences Ltd 相关性 - 货币/商品
WAVE Life Sciences Ltd 财务报表
Annual | 2023 |
营收: | $113.31M |
毛利润: | $104.10M (91.88 %) |
EPS: | $-0.540 |
FY | 2023 |
营收: | $113.31M |
毛利润: | $104.10M (91.88 %) |
EPS: | $-0.540 |
FY | 2022 |
营收: | $3.65M |
毛利润: | $-6.47M (-177.17 %) |
EPS: | $-2.05 |
FY | 2021 |
营收: | $40.96M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.36 |
Financial Reports:
No articles found.
WAVE Life Sciences Ltd
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。